Synuclein-gamma predicts poor clinical outcome in esophageal cancer patients

Basit Öğe Kaydı
dc.contributor.authorTastekin, Didem
dc.contributor.authorKargin, Suleyman
dc.contributor.authorKarabulut, Mehmet
dc.contributor.authorYaldiz, Naile
dc.contributor.authorTambas, Makbule
dc.contributor.authorGurdal, Necla
dc.contributor.authorTatli, Ali Murat
dc.date.accessioned2024-02-23T14:00:02Z
dc.date.available2024-02-23T14:00:02Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractThe synuclein gamma (SNCG) protein, a member of neuronal protein family synuclein, has been considered as a promising potential biomarker as an indicator of cancer stage and survival in patients with cancer. The present study was conducted to evaluate the prognostic value of SNCG in patients with esophageal carcinoma (EC). SNCG levels were assessed immunohistochemically in cancer tissues from 73 EC patients. Median age was 57 (range, 29-78) years old. Forty-seven percent of the patients were male. Thirty-seven percent of the patients had upper or middle localized tumor whereas 59 % had epidermoid carcinoma. More than half of the patients (61 %) had undergone operation where 57 % received adjuvant treatment including chemotherapy or chemotherapy plus radiotherapy. Median overall survival was 11.3 +/- 1.8 months (95% confidence interval (CI): 7.7-14.9 months). SNCG positivity was significantly associated with the histological type of EC and inoperability (for SNCG positive vs. negative group; epidermoid 80 vs. 53 %; p=0.05 and inoperable 59 vs. 32 %; p=0.04, respectively). Lymph node metastasis, inoperability and receiving no adjuvant treatment had significantly adverse effect on survival in the univariate analysis (p=0.01, p< 0.001, and p=0.001, respectively). SNCG positivity had significantly adverse effect on survival in both univariate and multivariate analysis (p=0.02 and p=0.01, respectively). Our results are the first to suggest that SNCG is a new independent predictor for poor prognosis in EC patients in the literature.en_US
dc.identifier.doi10.1007/s13277-014-2429-4
dc.identifier.endpage11877en_US
dc.identifier.issn1010-4283
dc.identifier.issn1423-0380
dc.identifier.issue12en_US
dc.identifier.pmid25142230en_US
dc.identifier.scopus2-s2.0-84925287088en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage11871en_US
dc.identifier.urihttps://doi.org/10.1007/s13277-014-2429-4
dc.identifier.urihttps://hdl.handle.net/20.500.12452/11428
dc.identifier.volume35en_US
dc.identifier.wosWOS:000346863700022en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofTumor Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSynuclein Gammaen_US
dc.subjectEsophageal Canceren_US
dc.subjectSurvivalen_US
dc.subjectPrognosisen_US
dc.titleSynuclein-gamma predicts poor clinical outcome in esophageal cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu